Amex (300896): The quarterly report is in line with expectations and shows growth resilience

Incident description The company released its 2024 quarterly report. 2024Q1 achieved operating income of 808 million yuan, a year-on-year increase of 28%, realized net profit of 527 million yuan, a year-on-year increase of 27%, and realized net profit deducted from non-mother 5

長江證券May 2 16:11

Bloomage BioTechnology Corporation Limited Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

It's shaping up to be a tough period for Bloomage BioTechnology Corporation Limited (SHSE:688363), which a week ago released some disappointing yearly results that could have a notable impact on how t

Simply Wall StMay 2 06:43

Huaxi Biotech (688363): Q1 performance improved markedly, medical and aesthetic business continued to grow

Core view: Incident: The company released an annual report and a quarterly report. In 2023, it achieved revenue of 6.076 billion yuan, a year-on-year decrease of 4.45%; net profit to mother was 593 million yuan, down 38.97% year on year; net profit after deducting net profit

廣發證券May 2 00:00

Aimeike (300896): Performance is in line with expectations, new product releases are expected

Investment Highlights 24Q1 profit was basically in line with the median performance forecast. After deducting non-net profit, the same increase was 37%. 24Q1: Revenue/net profit attributable to mothers/net profit deducted from non-net profit were $808/5.27/528 million, respectively, an increase of 28%/27%/

浙商證券May 1 00:00

Huaxi Biotech (688363): The inflection point in profitability in the first quarter showed leading growth in the medical terminal business

Revenue growth was steady in the first quarter of 2024, and net profit to mother increased 21%. The company's revenue in 2023 was 6.076 billion yuan, -4.45% year-on-year, and net profit to mother was 593 million yuan, or -38.97% year-on-year.

國信證券Apr 30 15:46

Huaxi Biotech (688363): Q1 surpassed expectations, high medical and aesthetic growth and significant cost reduction

Guide to this report: The company's performance in 2023 was under pressure. The 24Q1 improvement was obvious, and profit recovery exceeded expectations. The main reason was that high growth in medicine and beauty led to structural optimization of profit margins. At the same time, the medical, aesthetic and skincare sector had remarkable cost control results. Focus on subsequent skincare sector revenue

國泰君安Apr 30 13:56